PharmAsia News Business Bulletin
This article was originally published in Scrip
Executive Summary
A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
You may also be interested in...
Biocon Stays Upbeat On Oral Insulin Plans
India's largest biopharmaceutical company, Biocon, on May 17 sought to quell any confusion over its oral insulin program, underscoring that it stays confident of the molecule's prospects and is committed to taking it to the next stage of clinical development after the exit of partner Bristol-Myers Squibb (BMS).
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.